Published on: 15 July 2013
Skip to main content
Guidelines for the use of immunotherapy to treat patients with prostate carcinoma, hematologic malignances, and renal cell carcinoma were recently published as part of the Society for Immunotherapy of Cancer’s (SITC) Cancer Immunotherapy Guidelines series. These guidelines are the first of their kind and represent the result of a multidisciplinary collaboration between academic researchers and physicians, nurses, patients, and patients advocates from throughout the U.S.
Based on another SITC-led initiative, the SITC Immune Biomarkers Task Force recently published Volume I and Volume II of the guideline document, ‘Validation of biomarkers to predict response to immunotherapy in cancer’. Driven by the first Working Group (WG1) of the Immune Biomarkers Task Force, which includes representatives from academia, clinical medicine, government and industry, this report is the first to make evidence-based recommendations concerning the development, validation and regulation of biomarkers developed to predict response to cancer immunotherapy.
Immunotherapy-associated autoimmune hemolytic anemia
Uqba Khan, et al
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell...
James Godfrey, et al
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Eileen Shiuan, et al
Nivolumab induced myxedema crisis
Uqba Khan, et al
FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
Stefan N. Symeonides, et al
Immunotherapy resistance: the answers lie ahead – not in front – of us
Miles C. Andrews and Jennifer A. Wargo
Gene expression markers of Tumor Infiltrating Leukocytes
Patrick Danaher, et al
Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation
Mohanad H. Nada, et al
CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence...
Gray Kueberuwa, et al
Analyses of the peripheral immunome following multiple administrations of avelumab...
Renee N. Donahue, et al
Combination immunotherapy: a road map
Patrick A. Ott, et al
View all articles >
Recent articles RRS
Published on: 15 July 2013
Published on: 29 July 2013
Published on: 19 August 2014
Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.
JITC welcomes submissions to the following sections:
As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, the Society is pleased to offer its members waived article processing charges for manuscripts accepted in JITC through 2016.
Awards were presented during SITC’s 31st Annual Meeting to the first authors of two JITC articles, representing the Best Clinical/Translational and Best Basic Science Papers published in JITC. Congratulations to Zipei Feng, Sachin Puri, and Katherine Woods!
For more information please email firstname.lastname@example.org, call +1 414 271-2456, or visit http://sitcancer.org/journal.
The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member-driven society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The Society has become the forum for innovative discussions in the field.
Society members include nearly 1000 influential leaders and scientists engaged in tumor immunology and cancer immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC's members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.
It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Immune monitoring technology primers
Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.
SITC Cancer immunotherapy guidelines
Developed by experts in the treatment of specific types of cancer, each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.